Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFRvIII expression
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma (NCT04629209)
Phase 2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Withdrawn
Phase 2
Masonic Cancer Center, University of Minnesota
Withdrawn
Last update posted :
11/24/2023
Initiation :
06/28/2024
Primary completion :
12/31/2024
Completion :
06/30/2025
EGFR
|
EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression
|
dordaviprone (ONC201)
CART-EGFRvIII + Pembrolizumab in GBM (NCT03726515)
Phase 1
University of Pennsylvania
University of Pennsylvania
Completed
Phase 1
University of Pennsylvania
Completed
Last update posted :
06/22/2023
Initiation :
03/11/2019
Primary completion :
02/27/2021
Completion :
02/27/2021
EGFR • MGMT • TERT
|
EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation
|
Keytruda (pembrolizumab) • LXF821
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma (NCT00301418)
Phase 1/2
Northwell Health
Northwell Health
Completed
Phase 1/2
Northwell Health
Completed
Last update posted :
02/10/2016
Initiation :
03/01/2006
Primary completion :
05/01/2014
Completion :
05/01/2014
PTEN
|
EGFR overexpression • PTEN expression • EGFRvIII expression • PTEN overexpression • EGFRVIII overexpression
|
erlotinib
Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery (ZAP IT) (NCT00626015)
Phase 1
John Sampson
John Sampson
Completed
Phase 1
John Sampson
Completed
Last update posted :
01/21/2016
Initiation :
03/01/2007
Primary completion :
02/01/2013
Completion :
02/01/2013
IL2RA • CD4 • IL7R • ISG20
|
EGFRvIII expression
|
temozolomide • Rintega (rindopepimut) • Simulect (basiliximab) • Zinbryta (daclizumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login